01477.HK
Ocumension Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 5.10
−4.77%Year over year
Reported trailing growth
- Revenue
- +70.7%
- EBITDA
- +71.2%
- EBIT
- +56.3%
- EPS
- +53.5%
- Free cash flow
- -83.9%
- Operating cash flow
- +34.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +71.7%
- EBITDA
- +84.1%
- EBIT
- +47.7%
- Net income
- +40.8%
- EPS
- +48.7%
- Free cash flow
- +12.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026